Yoshiki Negi
Nishinomiya-hama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria.
Journal: Journal of cachexia, sarcopenia and muscle
Published: November 24, 2025
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.
Journal: Translational lung cancer research
Published: July 28, 2025
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.
Journal: Anticancer research
Published: July 08, 2025
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.
Journal: JTO clinical and research reports
Published: June 16, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.
Journal: Cancer research communications
Published: March 19, 2025
Successful Management of Steroid-Refractory Immune-Related Pneumonitis With Mycophenolate Mofetil: A Case Report.
Journal: Respirology case reports
Published: February 10, 2025
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Journal: Therapeutic advances in medical oncology
Published: February 07, 2025
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression.
Journal: Translational lung cancer research
Published: December 25, 2024
Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study.
Journal: Translational lung cancer research
Published: December 06, 2024
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.
Journal: Translational lung cancer research
Published: December 04, 2024
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 06, 2024
Last Updated: 09/26/2026